Kornimate/medical-research-clean huggingface dataset:
a diagnostic prediction model for prostate cancer in patients with pi-rads score 3

Conditions: Prostate Cancer

Summary: the goal of this observational study is to construct a predictive model for improving the diagnostic accuracy in patients with pi-rads score of 3. the main aims of this study are: * construct a diagnostic model of patients with pi-rads of score. * internal and external validation of the model. * decision curve analysis. the data of participants was collected retrospectively.

for patients with a pi-rads score of 3, the diagnosis of prostate cancer is still use prostate biopsy, but the detection rates of prostate cancer and clinically significant prostate cancer are approximately 30% and 15%. it can be seen that most patients with pi-rads 3 undergo unnecessary prostate biopsy and bear the risk of complications such as urinary tract infection. this makes most patients with pi-rads 3 choose to refuse invasive prostate biopsy. although researchers are committed to exploring biomarkers with high sensitivity and specificity, the application of biomarkers alone often cannot achieve the expected results. at present, the guidelines have recommended the use of diagnostic prediction models to assess patients' prostate cancer risk. doctors and patients use diagnostic models to assess the risk of prostate cancer before prostate biopsy. for patients with a low probability of cancer, biopsy can be temporarily avoided, which to a certain extent reduces the phenomenon of prostate cancer overdiagnosis. this study plans to work with multiple medical centers to conduct statistical analysis based on existing prostate cancer screening markers combined with patients' clinical data such as prostate volume, prostate-specific antigen density, apparent diffusion coefficient, pi-rads score and postoperative gleason score, and then construct a prostate cancer diagnostic model to improve the diagnostic accuracy of prostate cancer for patients with pi-rads score of 3. this will be of great significance for improving the early diagnosis of patients with pi-rads 3 and reducing unnecessary prostate puncture biopsies.

Eligibility criteria:
inclusion criteria: 1. patients with clinically suspected prostate cancer (abnormal psa level or dre); 2. all patients have undergone mpmri and have complete imaging data; 3. the pi-rads score of patients was 3; 4. prostate biopsy was performed and has clear pathological results. exclusion criteria: 1. the patient's serum tpsa is \ 100ng/ml; 2. repeated prostate biopsy; 3. the patient's clinical, imaging, or pathological data are incomplete.

Keywords: prostate cancer predictive model diagnosis prostate imaging-reporting and data system
a prospective, noninterventional, observational study of late-onset pompe disease

Conditions: Late-onset Pompe Patients Untreated or Treated With rhGAA

Summary: study 701-901, a multicenter, multinational, longitudinal, non-interventional observational study in subjects, at least 18 years old, diagnosed with late-onset pompe disease prospectively collects data to understand clinical progression in terms of respiratory function, symptomology, genotype, biochemistry, endurance and selected subject-reported measures for 24 weeks followed by a 240 week additional observation period for up to 100 subjects.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent after the nature of the study has been explained and prior to any study-related procedure * diagnosed with late-onset pompe disease based on current or previous genomic testing and/or endogenous gaa activity * at least 18 years of age at study entry * willing and able to comply with all study procedures exclusion criteria: * requires non-invasive ventilatory support while awake and in the upright position * concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the investigator, might compromise study completion or data collection * unable to perform baseline efficacy assessments
single dose ranging study of bi 1744 cl (olodaterol) in chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: primary objective: to investigate bronchodilator effect and safety of single doses of bi 1744 cl inhaled via respimat inhaler, secondary objective: to characterize pharmacokinetics of bi 1744 cl. olodaterol dose 40 mcg was investigated only in the open-label extension part for additional pk assessments which are not defined as primary or secondary endpoints.


Eligibility criteria:
inclusion criteria: 1. diagnosis of chronic obstructive pulmonary disease 2. smoking history of more than 10-pack years exclusion criteria: 1. history of asthma, allergic rhinitis, myocardial infarction or unstable of life-threatening cardiac arrhythmias 2. marked baseline prolongation of qt/qtc interval
lasmiditan compared to placebo in the acute treatment of migraine in korean

Conditions: Acute Migraine

Summary: a randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to placebo in the acute treatment of migraine


Eligibility criteria:
inclusion criteria: * able and willing to give written informed consent. * male or female, aged 18 years or above. * participants with migraine with or without aura fulfilling the international headache society (ihs) diagnostic criteria 1.1 and 1.2.1 (international headache classification (ichd-3). * history of disabling migraine for at least 1 year. * migraine disability association (midas) score ≥11. * migraine onset before the age of 50 years. * history of 3 - 8 migraine attacks per month (\< 15 headache days per month). * females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (iud), abstinence or vasectomized partner). * able and willing to complete an electronic diary to record details of the migraine attack treated with study drug. exclusion criteria: * any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study. * pregnant or breast-feeding women. * known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan. * history or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures. * history of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (bppv), meniere's disease, vestibular migraine, and other vestibular disorders. * history of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy). * history within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol. * history of orthostatic hypotension with syncope. * significant renal or hepatic impairment. * participant is at imminent risk of suicide (positive response to question 4 or 5) on the columbia-suicide severity rating scale (c-ssrs) or had a suicide attempt within six months prior to screening. * participation in any clinical trial of an experimental drug or device in the previous 30 days. * known hepatitis b or c or human immunodeficiency virus(hiv) infection. history, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month. * use of more than 3 doses per month of either opiates or barbiturates. * initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to screening/visit 1.
pressure wave guided atrial fibrillation cryoablation

Conditions: Atrial Fibrillation

Summary: prospective multicenter observational study evaluating the performance of pressure wave-guided atrial fibrillation cryoablation used in accordance with clinical practice guidelines.

the polar-wave registry is a prospective, multi-center, single-arm study evaluating the efficacy and safety of pressure-guided atrial fibrillation cryoablation, where the occlusion of pulmonary veins will be assessed by pressure waveforms (instead of contrast), over a follow-up period of 12 months. this is a non-commercial, investigator-driven clinical study, coordinated by the main investigator from university hospital "12th of october", madrid, spain. several responsibilities are delegated to the clinical research unit (university hospital "12th of october", madrid, spain). the study was planned according to the good clinical practices. polar-wave study has been approved by the ethics committee and spanish health authorities. all participating patients must give written informed consent.

Eligibility criteria:
inclusion criteria: * age over 18 years. * paroxysmal, persistent, or long-lasting persistent atrial fibrillation. * indication of pulmonary vein ablation according to clinical practice guidelines. exclusion criteria: * previous ablation of atrial fibrillation. * thrombus in the left atrium. * rheumatic heart disease. * hypertrophic cardiomyopathy. * absolute contraindication to anticoagulation. * women in a state of pregnancy, lactation or childbearing age without contraception. * life expectancy \< 1 year.

Keywords: atrial fibrillation cryoablation pressure waveforms
effects of a physical exercise program on patients affected with fibromyalgia

Conditions: Fibromyalgia

Summary: physical activity has been used for a number of years in the treatment of fibromyalgia (fm). the main objective of this study is to compare the effects of physical activity on two groups of women diagnosed with fibromyalgia (fm) in terms of pain, quality of life and the impact of the condition on their daily lives. methods: this was a randomized clinical trial to assess the effects of physical activity performed by subjects assigned to one of two groups on the scores of three questionnaires (the pain visual analogue scale, the fiq questionnaire and the sf-36 health questionnaire) administered before and after the intervention.


Eligibility criteria:
inclusion criteria: women * ages of 40 and 75 * diagnosis fibromyalgia (code m79.7) * anoia region exclusion criteria: * pregnant * unable to participate in the physical activity program.

Keywords: physical activity fibromyalgia pain exercice quality of live
novel subtypes of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: to classify subtypes of polycystic ovary syndrome (pcos) using machine-learning algorithms, and compare the reproductive and metabolic characteristics and ivf outcomes across these identified subtypes.

in this study, we've developed a machine-learning model to classify pcos patients into four subtypes based on nine clinical characteristics. the goal of this observational study is to: * learn about different pcos subtypes using our classification model. * compare the reproductive and metabolic features of these subtypes. * assess the outcomes of ivf among different pcos subtypes. * prospective 6.5-year follow-up data will be collected. participants will: * undergo a telephone interview to gather details on: 1. current physical stats like height and weight. 2. reproductive history, including pregnancies and childbirths in recent years. 3. details about any ivf treatments. 4. current status of conditions such as pcos, type 2 diabetes, hypertension, and dyslipidemia. * be invited for a physical examination that includes: 1. measurements such as height, weight, blood pressure, and body circumferences. 2. laboratory tests for endocrine and metabolic conditions. 3. ultrasound scans of the ovaries and liver.

Eligibility criteria:
inclusion criteria: * pcos patients diagnosed using the rotterdam criteria, which requires the presence of at least two of the following: 1. menstrual irregularities: a menstrual cycle length of fewer than 21 days or more than 35 days, and/or fewer than eight cycles per year. 2. hyperandrogenism: defined either by an elevated total testosterone level (as per local laboratory criteria) or by a modified ferriman-gallwey (mfg) score of 5 or higher. 3. polycystic ovaries on ultrasound: presence of 12 or more follicles measuring 2-9 mm in diameter in each ovary and/or an ovarian volume exceeding 10 ml. exclusion criteria: patients with congenital adrenal hyperplasias, androgen-secreting tumours, or cushing's syndrome) will be excluded.
ultrasound-guided ficb for proximal femoral osteotomy in pediatric patients

Conditions: Orthopedic Disorder

Summary: this prospective randomized controlled trial aims to examine the effect of fascia iliaca compartment block on the postoperative pain and opioid consumption in pediatric patients (3y≤ age \<18y) who will undergo orthopedics surgery (proximal femoral osteotomy). patients will be allocated to either the ficb(fascia iliaca compartment block + iv pca) group or the control group (no block + iv pca). fascia iliaca compartment block will be performed using 0.25% ropivacaine (1ml/kg, max 30ml) under ultrasound-guidance at the end of surgery. the total opioid consumption at 12, and 24 hours after the surgery, and the pain score at 10 min after pacu admin, 1,6,24 hours after the surgery, the total dose of additional rescue analgesia (intravenous ketorolac or nalbuphine) at 12 and 24 hours after the surgery will be recorded.

this prospective randomized controlled trial aims to examine the effect of fascia iliaca compartment block on postoperative pain and opioid consumption in pediatric patients (3y≤ age \<18y) who will undergo orthopedics surgery (proximal femoral osteotomy). patients will be allocated to either the ficb(fascia iliaca compartment block + iv pca) group or the control group (no block + iv pca). fascia iliaca compartment block will be performed using 0.25% ropivacaine (1ml/kg, max 30ml) under ultrasound-guidance at the end of surgery. the total opioid consumption at 12, and 24 hours after the surgery, and the pain score at 10 min after pacu admin, 1,6,24 hours after the surgery, the total dose of additional rescue analgesia (intravenous ketorolac or nalbuphine) at 12 and 24 hours after the surgery will be recorded.

Eligibility criteria:
inclusion criteria: - 36 children aged between 3 and 18 years who undergo proximal femoral osteotomy exclusion criteria: * complex surgery (other than proximal femoral osteotomy) * allergy to opioid * allergy to local anesthetics * disease in heart, lung, kidney, and liver * coagulation disorder * disease in the central and peripheral nervous system * unstable vital sign * significant renal impairment (creatinine\> 3.0 mg/dl) * significant hepatic impairment (aspartate transaminase\> 120 unit/l, alanine aminotransferase\> 120 unit/l)
a pilot study to assess the efficacy and safety of folic acid and/or vitamin b complex on hepatitis c infected patients treated with pegylated interferon and ribavirin.

Conditions: Hepatitis C

Summary: since success of the combination therapy with peg-ifn and rbv is contingent on maintaining adequate doses of both drugs throughout the treatment period, the emergence of hematological side effects is expected and requires intervention. the hematological adverse effects lead to a trade-off between continuing the treatment with optimal dosage, to clear the virus, exacerbating thereby the side effects versus decreasing dosage to relieve severe anemia, reducing thereby the chances of achieving sustained virological response (svr). therefore, we aimed at giving folic acid® and neurobion® to hcv-infected patients during treatment with different types of peg-ifn plus ribavirin in an attempt to evaluate its efficacy and safety as a prophylactic treatment to prevent hematological adverse effects. preventing adverse effects without interfering with the therapeutic efficacy of different types of peg-ifn plus ribavirin in hcv patients will lead to better health outcomes and improvement in their quality of life (hrqol).


Eligibility criteria:
inclusion criteria: chronic hepatitis c patients of both sexes were eligible for inclusion if they were hcv rna positive, naive to peg-inf and rbv, and had abnormal serum alanine transaminase levels on two occasions during the preceding six months. exclusion criteria: patients with significant hematological abnormalities at baseline, such as neutropenia (anc \<1200 x 103 cells/µl), thrombocytopenia (\<70 x 103 cells/ µl), and anemia (\<10.5 g/dl), were excluded. patients were also excluded from study participation if they had serum creatinine ≥1.70 mg/dl (150 µmol), hepatitis b surface antigen positivity, decompensated cirrhosis, or other forms of liver disease not attributable to hcv. patients with severe depression or psychosis, uncontrolled seizures, poorly controlled cardiovascular disease, diabetes mellitus, or autoimmune disorders were also ineligible. women were ineligible for study participation if they were pregnant or unwilling to use at least 2 forms of effective contraception during the entire study period.
computerized cognitive training in epilepsy

Conditions: Epilepsy

Summary: the purpose of this randomized uncontrolled single-site trial is to evaluate the efficacy of two novel computerized cognitive enhancing software packages for improving cognitive and behavioral outcomes in patients with epilepsy.

the proposed investigation will be the first to pit two software packages against each other to evaluate the relative efficacy and feasibility of their use among patients with epilepsy. pharmacotherapy fails to control seizures in approximately 30% of patients. use of non-pharmacologic interventions, such as cognitive rehabilitation, has shown some benefit for improving cognitive functions and reducing mood symptoms. each of the computer exercises employ a set of stimuli that are generalizable and mimic real-world experiences.

Eligibility criteria:
inclusion criteria: * documented diagnosis of epilepsy based on medical records. the records will be reviewed by the pi and the approved study personnel to confirm that a diagnosis of epilepsy has been made. * must own a computer or have access to the internet. exclusion criteria: * full scale iq \< 80, as assessed by the wasi-ii. * history of chronic progressive neurologic or neurodegenerative illnesses (e.g., parkinson's disease, multiple sclerosis, dementia, primary or metastatic malignancy). patients with headache or migraine are not excluded. * history of axis i psychiatric illness with psychotic features. (e.g., schizophrenia). patients with depression or anxiety (treated or untreated) without psychotic features are not excluded. * visual or auditory impairment, which precludes participation in part, or all of the testing. * english as a first language will not be required, but participants must have either received some of their schooling in english or used english in their work for \>10 years.
research on the optimized treatment method for apatinib's cure of advanced gastric cancer

Conditions: Two Different Treatment Methods

Summary: the investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. one is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.


Eligibility criteria:
inclusion criteria: 1. male and female patients,age≥18years 2. confirmed by pathology or histology of gastric cancer 3. patients who failed first-line chemotherapy 4. the ecog physical status score:0 to 2 5. expected survival ≥3months 6. patients should be voluntary to the trail and provide with signed informed consent. 7. the researchers believe patients can benefit from the study. exclusion criteria: 1. pregnant or lactating women 2. patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories 3. patients with apatinib contraindications 4. patients of doctors considered unsuitable for the trail
the effection pain and anxiety of a breathing exercise applied following laparoscopic cholecystectomy

Conditions: Anxiety; Pain

Summary: one important part of individual nursing care is that that nurses teach and apply breathing exercises, which are vital and increase the patient's quality of life, in the light of their current knowledge and skills. the purpose of this study was therefore to determine the effect of postoperative breathing exercises on pain and anxiety in patients hospitalized in the general surgery clinic and who had undergone laparoscopic cholecystectomy.

introduction: several methods are employed for overcoming pain and anxiety that are frequently experienced in the postoperative period. this study was planned to determine the effect of a breathing exercise on patient pain and anxiety after laparoscopic cholecystectomy. methods: the sample determined using power analysis in this randomized, controlled, semi-experimental research performed in two hospitals in the west of turkey between january and november 2019 consisted of 74 individuals (37 experimental and 37 controls). an information form involving descriptive characteristics, a visual analogue scale (vas), and the state-trait anxiety inventory (stai i/ii) were used for data collection. descriptive statistical methods and parametric tests were employed in the data analysis.

Eligibility criteria:
inclusion criteria * hospitalized in the general surgery clinics, * with histories of laparoscopic cholecystectomy, * consenting to take part. exclusion criteria: - have a psychiatric disorders.